ischemic stroke
Conditions
Interventions
Experimental Group :Levosimendan in addition to standard therapy
Sponsors
the First Hospital of Jilin University.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. age >= 18 years and gender; 2. a definitive clinical diagnosis of acute ischaemic stroke with an NIHSS score of >=6, =2; 3. pre-morbidity mRS score <= 1; 4. patient or immediate family able and willing to sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. patients receiving emergency reperfusion therapy (including intravenous thrombolysis and mechanical thrombolysis); 2. history of intracranial haemorrhagic disease confirmed by imaging; 3. Accompanied by seizures; 4. cardiac disease: diagnosis of acute coronary syndrome within 30 days prior to onset, severe ventricular outflow tract obstruction disease (e.g., hypertrophic or restrictive cardiomyopathy, severe cardiac valvular disease) clearly defined by cardiac ultrasound, and history of tip-twisting ventricular tachycardia; 5. Use of cardiotonic or antihypertensive drugs (milrinone, digitalis, dobutamine, etc.) within 3 days prior to onset of symptoms; use of levosimendan within 30 days prior to onset of symptoms; and use of cerebral vasodilators of the calcium antagonist class or the prostaglandin class after onset of symptoms (e.g., nimodipine, prostaglandins, fasudil, beclomethasone sodium, etc.); 6. Baseline systolic blood pressure =200 mmHg or diastolic blood pressure >=120 mmHg after drug control, and baseline heart rate >=120 beats/minute; 7. serum potassium < 3.5 mmol/l prior to drug initiation; 8. severe hepatic or renal insufficiency; 9. patients with a life expectancy of less than 3 months, pregnant or lactating women, or patients who are otherwise unable to complete the study; 10. those who are participating in other clinical studies or have participated in other clinical studies within 3 months prior to enrolment; 11. Any other circumstances that the investigator considers unsuitable for enrolment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of 90+-7 day mRS scores 0-1; | — |
Secondary
| Measure | Time frame |
|---|---|
| NIHSS at discharge/7 days;Proportion of 90+-7 day mRS scores 0-2;Distribution of 90+-7 day mRS scores;Ultimate infarct volume.;Change in NIHSS scores before and after treatment.; | — |
Countries
China
Contacts
Public ContactYang Ge
the First Hospital of Jilin University.
Outcome results
None listed